After a positive FDA panel for Aimmune’s and FDA decision looming, we will discuss the commercial potential of Palforzia. NOTE: Call will have a proprietary survey, run by SI, of high volume pediatric allergists/immunologists available.
Tag: STATExpertAdvantage
STAT Expert Advantage
A Look at the Breast Cancer Landscape: An Expert’s Take on the Newly Approved Daiichi Sankyo Drug, ENHERTU, SGEN’s tucatinib, & the Role of IO therapy
STAT Expert Advantage
A Look at the Breast Cancer Landscape: An Expert’s Take on the Newly Approved Daiichi Sankyo Drug, ENHERTU, SGEN’s tucatinib, & the Role of IO therapy
STAT Expert Advantage
A Look at the Breast Cancer Landscape: An Expert’s Take on the Newly Approved Daiichi Sankyo Drug, ENHERTU, SGEN’s tucatinib, & the Role of IO therapy
STAT Expert Advantage
Exploring gene therapy treatments in the hemophilia space including those from BioMarin, Spark Therapeutics, and UniQure
STAT Expert Advantage
Exploring gene therapy treatments in the hemophilia space including those from BioMarin, Spark Therapeutics, and UniQure
STAT Expert Advantage
Exploring gene therapy treatments in the hemophilia space including those from BioMarin, Spark Therapeutics, and UniQure
STAT Expert Advantage
Exploring gene therapy treatments in the hemophilia space including those from BioMarin, Spark Therapeutics, and UniQure
STAT Expert Advantage
How will companies, patients, and the FDA navigate the impact of COVID-19 on Clinical Trials? A conversation with the former Director of the FDA Orphan Drug Division.
STAT Expert Advantage
How will companies, patients, and the FDA navigate the impact of COVID-19 on Clinical Trials? A conversation with the former Director of the FDA Orphan Drug Division.
